{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:45:55Z","timestamp":1791877555830,"version":"4.3.4"},"reference-count":133,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hidradenitis suppurativa (HS) is a chronic, recurrent and progressively destructive inflammatory disease associated with substantial physical, psychological and social burden. The therapeutic landscape of HS has rapidly evolved with the introduction of biologics targeting TNF\u2010\u03b1 and IL\u201017 pathways, increasing use of metabolic and hormonal interventions and growing integration of surgery with systemic therapy. However, despite expanding treatment options, many patients continue to experience incomplete disease control, progressive tunnel formation and cumulative disability. This narrative review discusses optimization of currently available medical therapies in HS, with a particular focus on treatment sequencing, rational combination strategies and treat\u2010to\u2010target principles. Rather than viewing therapies as isolated interventions, modern HS management increasingly requires dynamic, phenotype\u2010driven integration of biologics, antibiotics, hormonal and metabolic therapies and surgery according to inflammatory burden, structural disease and comorbidities. We discuss the evolving role of systemic antibiotics as time\u2010limited induction therapies rather than chronic suppressive treatment, practical approaches to biologic sequencing and dose optimization and the emerging rationale for combining biologic therapy with metabolic or procedural interventions. The review also highlights the importance of early inflammatory control within a potential therapeutic \u2018window of opportunity\u2019 to prevent irreversible tunnel formation and long\u2010term structural damage. In parallel, patient\u2010reported outcomes, pain control and quality of life are increasingly recognized as essential therapeutic targets alongside objective inflammatory measures such as HiSCR and IHS4. Ultimately, optimization of HS therapy should aim not merely at short\u2010term reduction of inflammatory lesions but at long\u2010term modification of disease trajectory, prevention of irreversible disability and restoration of quality of life through individualized, multidimensional and strategically integrated care.<\/jats:p>","DOI":"10.1111\/jdv.70787","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:55:04Z","timestamp":1791874504000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing therapy in hidradenitis suppurativa: Combination, sequencing and treat\u2010to\u2010target"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2067-4929","authenticated-orcid":false,"given":"\u0141ukasz","family":"Matusiak","sequence":"first","affiliation":[{"name":"Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine Wroclaw University of Science and Technology  Wroclaw Poland"},{"name":"Department of Dermato\u2010Venereology 4th Military Hospital  Wroclaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Dzi\u0119ga\u0142a","sequence":"additional","affiliation":[{"name":"Department of Dermato\u2010Venereology 4th Military Hospital  Wroclaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[{"name":"The Charles Centre, Department of Dermatology St Vincent's University Hospital  Dublin Ireland"},{"name":"Charles Institute of Dermatology, School of Medicine University College Dublin  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Knecht\u2010Gurwin","sequence":"additional","affiliation":[{"name":"Department of Dermato\u2010Venereology 4th Military Hospital  Wroclaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6882-2113","authenticated-orcid":false,"given":"Alejandro","family":"Molina Leyva","sequence":"additional","affiliation":[{"name":"Dermatology Department Hospital Universitario Virgen de Las Nieves\u2010Ibs. Granada  Granada Spain"},{"name":"Dermatology Deparment Univeristy of Granada  Granada Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8160-4169","authenticated-orcid":false,"given":"Angelo V.","family":"Marzano","sequence":"additional","affiliation":[{"name":"Dermatology Unit Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico  Milan Italy"},{"name":"Department of Pathophysiology and Transplantation Universit\u00e0 Degli Studi di Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztian","family":"Nemeth","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venerology and Dermatooncology Semmelweis University  Budapest Hungary"},{"name":"ProHealth Medical Group  New Berlin Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine Wroclaw University of Science and Technology  Wroclaw Poland"},{"name":"Department of Dermato\u2010Venereology 4th Military Hospital  Wroclaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"e_1_2_21_2_1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/jdv.20472","article-title":"European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: treatment","volume":"39","author":"Zouboulis CC","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"e_1_2_21_3_1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.13090","article-title":"Risk factors, clinical course and long\u2010term prognosis in hidradenitis suppurativa: a cross\u2010sectional study","volume":"171","author":"Kromann CB","year":"2014","journal-title":"Br J Dermatol"},{"issue":"2","key":"e_1_2_21_4_1","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jaad.2020.03.041","article-title":"The prevalence and odds of anxiety and depression in children and adults with hidradenitis suppurativa: systematic review and meta\u2010analysis","volume":"83","author":"Jalenques I","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"e_1_2_21_5_1","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1111\/bjd.16603","article-title":"Profound consequences of hidradenitis suppurativa: a review","volume":"183","author":"Matusiak \u0141","year":"2020","journal-title":"Br J Dermatol"},{"key":"e_1_2_21_6_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40257-026-01011-8","article-title":"Defining moderate disease and progression in hidradenitis suppurativa: an expert framework to unlock the window of opportunity for prompt treatment","volume":"27","author":"Martorell A","year":"2026","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"e_1_2_21_7_1","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaad.2019.12.044","article-title":"Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: a post hoc analysis of PIONEER 1 and 2 individual patient data","volume":"82","author":"Frew JW","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_21_8_1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jac\/dkv361","article-title":"Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients","volume":"71","author":"Join\u2010Lambert O","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_21_9_1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamadermatol.2023.6201","article-title":"Efficacy and durability of intravenous ertapenem therapy for recalcitrant hidradenitis suppurativa","volume":"160","author":"Nosrati A","year":"2024","journal-title":"JAMA Dermatol"},{"key":"e_1_2_21_10_1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamadermatol.2023.6197","article-title":"Balancing ertapenem therapy in recalcitrant hidradenitis suppurativa with antibiotic stewardship","volume":"160","author":"Naik HB","year":"2024","journal-title":"JAMA Dermatol"},{"key":"e_1_2_21_11_1","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2179368","article-title":"Intramuscular ertapenem for the treatment of severe cases hidradenitis suppurativa","volume":"34","author":"Segura Palacios JM","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"e_1_2_21_12_1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaad.2020.01.007","article-title":"Rifampin\u2010moxifloxacin\u2010metronidazole combination therapy for severe Hurley stage 1 hidradenitis suppurativa: prospective short\u2010term trial and 1\u2010year follow\u2010up in 28 consecutive patients","volume":"88","author":"Delage M","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_21_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70264"},{"key":"e_1_2_21_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2025.2572884"},{"key":"e_1_2_21_15_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaad.2016.08.001","article-title":"Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa","volume":"76","author":"Fischer AH","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"e_1_2_21_16_1","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the international hidradenitis suppurativa severity score system (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis CC","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"e_1_2_21_17_1","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/jid.2012.472","article-title":"Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross\u2010sectional study","volume":"133","author":"Canoui\u2010Poitrine F","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"5","key":"e_1_2_21_18_1","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jaad.2015.07.047","article-title":"New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes","volume":"73","author":"Zee HH","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"e_1_2_21_19_1","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/ijd.17861","article-title":"Severity and therapeutic decisions based on lesion location in patients with hidradenitis suppurativa","volume":"64","author":"Mu\u00f1oz\u2010Barba D","year":"2025","journal-title":"Int J Dermatol"},{"issue":"6","key":"e_1_2_21_20_1","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/jdv.16183","article-title":"Defining hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study","volume":"34","author":"Martorell A","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"e_1_2_21_21_1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jum.16351","article-title":"Update on ultrasound diagnostic criteria and new ultrasound severity and activity scorings of hidradenitis suppurativa: modified SOS\u2010HS and US\u2010HSA","volume":"43","author":"Wortsman X","year":"2024","journal-title":"J Ultrasound Med"},{"key":"e_1_2_21_22_1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/jdv.20600","article-title":"International consensus statement on the use of ultrasound in hidradenitis suppurativa","volume":"40","author":"Wortsman X","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"e_1_2_21_23_1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/bjd\/ljae216","article-title":"Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life","volume":"191","author":"Lyons D","year":"2024","journal-title":"Br J Dermatol"},{"issue":"2","key":"e_1_2_21_24_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000473873","article-title":"A disease\u2010modifying approach for advanced hidradenitis suppurativa (regimen with metformin, liraglutide, dapsone, and finasteride): a case report","volume":"9","author":"Khandalavala BN","year":"2017","journal-title":"Case Rep Dermatol"},{"issue":"8","key":"e_1_2_21_25_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24086969","article-title":"Metformin treatment of hidradenitis suppurativa: effect on metabolic parameters, inflammation, cardiovascular risk biomarkers, and immune mediators","volume":"24","author":"Hambly R","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"12","key":"e_1_2_21_26_1","doi-asserted-by":"crossref","DOI":"10.1007\/s11916-017-0647-3","article-title":"Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa","volume":"21","author":"Patel ZS","year":"2017","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"e_1_2_21_27_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan A","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_21_28_1","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15439","article-title":"Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild\u2010to\u2010moderate hidradenitis suppurativa: a retrospective study","volume":"35","author":"Molinelli E","year":"2022","journal-title":"Dermatol Ther"},{"key":"e_1_2_21_29_1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaad.2023.08.064","article-title":"Clascoterone in the treatment of mild hidradenitis suppurativa","volume":"90","author":"Hargis A","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_21_30_1","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jaad.2025.10.149","article-title":"Efficacy and safety of ruxolitinib cream in patients with mild to moderate hidradenitis suppurativa: results from a randomized, double\u2010blind, vehicle\u2010controlled phase 2 study","volume":"94","author":"Porter ML","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_21_31_1","doi-asserted-by":"crossref","DOI":"10.1007\/s13671-024-00456-6","article-title":"Injectable triamcinolone therapy for hidradenitis suppurativa: a systematic review and treatment recommendations","volume":"14","author":"Islam Z","year":"2025","journal-title":"Curr Derm Rep"},{"key":"e_1_2_21_32_1","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1159\/000524121","article-title":"Intralesional treatments in hidradenitis suppurativa: a systematic review","volume":"238","author":"Cuenca\u2010Barrales C","year":"2022","journal-title":"Dermatology"},{"key":"e_1_2_21_33_1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.det.2024.12.010","article-title":"Addressing the dressings: wound Care in Hidradenitis Suppurativa","volume":"43","author":"Hickerson N","year":"2025","journal-title":"Dermatol Clin"},{"key":"e_1_2_21_34_1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000499934","article-title":"Intralesional triamcinolone for fistulous tracts in hidradenitis suppurativa: an uncontrolled prospective trial with clinical and ultrasonographic follow\u2010up","volume":"236","author":"\u00c1lvarez P","year":"2020","journal-title":"Dermatology"},{"key":"e_1_2_21_35_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ijd.15124","article-title":"Efficacy of high\u2010dose intralesional triamcinolone for hidradenitis suppurativa","volume":"60","author":"Garelik J","year":"2021","journal-title":"Int J Dermatol"},{"key":"e_1_2_21_36_1","article-title":"Infliximab in hidradenitis suppurativa: a systematic review and meta\u2010analysis","volume":"35","author":"Shih T","year":"2022","journal-title":"Dermatol Ther"},{"key":"e_1_2_21_37_1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1177\/12034754231188319","article-title":"Efficacy and patient satisfaction associated with intramuscular triamcinolone therapy for acute flares of hidradenitis suppurativa","volume":"27","author":"Benesh G","year":"2023","journal-title":"J Cutan Med Surg"},{"key":"e_1_2_21_38_1","doi-asserted-by":"crossref","DOI":"10.1097\/JW9.0000000000000162","article-title":"Prednisone and amoxicillin\/clavulanic acid for the treatment of hidradenitis suppurativa flares: a prospective observational study","volume":"10","author":"Gibson RS","year":"2024","journal-title":"Int J Womens Dermatol"},{"key":"e_1_2_21_39_1","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.adengl.2020.10.023","article-title":"Systemic steroids in the Management of Moderate\u2010to\u2010severe Hidradenitis Suppurativa","volume":"111","author":"Duarte B","year":"2020","journal-title":"Actas Dermo\u2010Sifiliogr\u00e1ficas (English Edition)"},{"key":"e_1_2_21_40_1","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1016\/j.jaad.2012.06.011","article-title":"Recalcitrant severe hidradenitis suppurativa successfully treated with cyclosporine a","volume":"67","author":"Bianchi L","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_21_41_1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/09546634.2015.1088128","article-title":"Cyclosporine treatment of severe hidradenitis suppurativa\u2010a case series","volume":"27","author":"Anderson MD","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"e_1_2_21_42_1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2005.10.004","article-title":"Tetracyclines: nonantibiotic properties and their clinical implications","volume":"54","author":"Sapadin AN","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_21_43_1","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/exd.14531","article-title":"Mechanism of anti\u2010inflammatory effects of rifampicin in an ex\u00a0vivo culture system of hidradenitis suppurativa","volume":"31","author":"Haferland I","year":"2022","journal-title":"Exp Dermatol"},{"issue":"1","key":"e_1_2_21_44_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1128\/AAC.47.1.363-367.2003","article-title":"Clindamycin modulates inflammatory\u2010cytokine induction in lipopolysaccharide\u2010stimulated mouse peritoneal macrophages","volume":"47","author":"Nakano T","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_21_45_1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2020.12.089","article-title":"The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a prospective European cohort study","volume":"85","author":"Straalen KR","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_21_46_1","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaad.2018.11.035","article-title":"Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasound observations","volume":"80","author":"Caposiena Caro RD","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"e_1_2_21_47_1","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug\u2010susceptible tuberculosis","volume":"63","author":"Nahid P","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"e_1_2_21_48_1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cmi.2016.10.002","article-title":"The use of rifampin in staphylococcal orthopaedic\u2010device\u2010related infections","volume":"23","author":"Sendi P","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"e_1_2_21_49_1","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/jdv.19725","article-title":"Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa","volume":"38","author":"Aarts P","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"e_1_2_21_50_1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40257-019-00442-w","article-title":"Is there a role for antiandrogen therapy for hidradenitis suppurativa? A systematic review of published data","volume":"20","author":"Nikolakis G","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"e_1_2_21_51_1","first-page":"263","article-title":"Hormonal therapies for hidradenitis suppurativa: review","volume":"28","author":"Kraft JN","year":"2010","journal-title":"Dermatol Clin"},{"issue":"1","key":"e_1_2_21_52_1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaad.2018.06.063","article-title":"Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa","volume":"80","author":"Golbari NM","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"e_1_2_21_53_1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.36849\/jdd.7325","article-title":"Hormonal treatments in hidradenitis suppurativa: a systematic review","volume":"22","author":"Masson R","year":"2023","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"e_1_2_21_54_1","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.jaad.2024.09.015","article-title":"Antibiotic, hormonal\/metabolic, and retinoid therapies for hidradenitis suppurativa","volume":"91","author":"Fonjungo FE","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"e_1_2_21_55_1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.det.2024.12.007","article-title":"Hidradenitis suppurativa management with antibiotics and systemic therapies","volume":"43","author":"Kirchner S","year":"2025","journal-title":"Dermatol Clin"},{"issue":"23","key":"e_1_2_21_56_1","doi-asserted-by":"crossref","first-page":"15250","DOI":"10.3390\/ijms232315250","article-title":"The role of hormones in hidradenitis suppurativa: a systematic review","volume":"23","author":"Abu Rached N","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10","key":"e_1_2_21_57_1","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamadermatol.2025.2723","article-title":"Glucagon\u2010like Peptide\u20101 receptor agonists in hidradenitis suppurativa","volume":"161","author":"Gouvrion L","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"1","key":"e_1_2_21_58_1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon\u2010like peptide 1 receptor activation inhibits toll\u2010like receptor agonist\u2010induced inflammation","volume":"36","author":"Wong CK","year":"2024","journal-title":"Cell Metab"},{"issue":"12","key":"e_1_2_21_59_1","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.jid.2025.08.045","article-title":"GLP\u20101 receptor agonists as emerging modulators of inflammation and angiogenesis in chronic cutaneous wound healing","volume":"145","author":"Ghebrehiwet\u2010Kuflom J","year":"2025","journal-title":"J Invest Dermatol"},{"key":"e_1_2_21_60_1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s13555-024-01169-1","article-title":"Topical and systemic retinoids in the Management of Hidradenitis Suppurativa: a comprehensive literature review","volume":"14","author":"Molinelli E","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"e_1_2_21_61_1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000329023","article-title":"Dapsone therapy for hidradenitis suppurativa: a series of 24 patients","volume":"222","author":"Yazdanyar S","year":"2011","journal-title":"Dermatology"},{"issue":"4","key":"e_1_2_21_62_1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/09546634.2019.1601668","article-title":"The contradictory inefficacy of methotrexate in hidradenitis suppurativa: a need to revise pathogenesis or acknowledge disease heterogeneity?","volume":"31","author":"Frew JW","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"e_1_2_21_63_1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","article-title":"Hidradenitis suppurativa","volume":"405","author":"Sabat R","year":"2025","journal-title":"Lancet"},{"key":"e_1_2_21_64_1","unstructured":"US Food and Drug Administration.Humira (adalimumab) injection for subcutaneous use: prescribing information.2025. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125057s424lbl.pdf."},{"key":"e_1_2_21_65_1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball AB","year":"2016","journal-title":"N Engl J Med"},{"key":"e_1_2_21_66_1","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate\u2010to\u2010severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball AB","year":"2012","journal-title":"Ann Intern Med"},{"key":"e_1_2_21_67_1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR, a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo\u2010controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball AB","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"e_1_2_21_68_1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","article-title":"Long\u2010term adalimumab efficacy in patients with moderate\u2010to\u2010severe hidradenitis suppurativa\/acne inversa: 3\u2010year results of a phase 3 open\u2010label extension study","volume":"80","author":"Zouboulis CC","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"e_1_2_21_69_1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/ced.14448","article-title":"Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab","volume":"46","author":"Frew JW","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"e_1_2_21_70_1","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","article-title":"Efficacy and safety of adalimumab in conjunction with surgery in moderate\u2010to\u2010severe hidradenitis suppurativa: the SHARPS randomized clinical trial","volume":"156","author":"Bechara FG","year":"2021","journal-title":"JAMA Surg"},{"key":"e_1_2_21_71_1","unstructured":"US Food and Drug Administration.Cosentyx (secukinumab) injection for subcutaneous or intravenous use: prescribing information.2024. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125504s082lbl.pdf"},{"issue":"4","key":"e_1_2_21_72_1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/17460441.2025.2482058","article-title":"The preclinical discovery and development of secukinumab for the treatment of moderate\u2010to\u2010severe hidradenitis suppurativa","volume":"20","author":"Knecht\u2010Gurwin K","year":"2025","journal-title":"Expert Opin Drug Discovery"},{"key":"e_1_2_21_73_1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate\u2010to\u2010severe hidradenitis suppurativa: SUNSHINE and SUNRISE, week 16 and week 52 results of two identical, multicentre, randomised, placebo\u2010controlled, double\u2010blind phase 3 trials","volume":"401","author":"Kimball AB","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"e_1_2_21_74_1","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/bjd\/ljae098","article-title":"Secukinumab in patients with moderate\u2010to\u2010severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials","volume":"190","author":"Zouboulis CC","year":"2024","journal-title":"Br J Dermatol"},{"issue":"4","key":"e_1_2_21_75_1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/bjd\/ljae442","article-title":"The roles of interleukin (IL)\u201017A and IL\u201017F in hidradenitis suppurativa pathogenesis: evidence from human in\u00a0vitro preclinical experiments and clinical samples","volume":"192","author":"Rastrick J","year":"2025","journal-title":"Br J Dermatol"},{"key":"e_1_2_21_76_1","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL\u201017A and IL\u201017F","volume":"11","author":"Adams R","year":"2020","journal-title":"Front Immunol"},{"issue":"10443","key":"e_1_2_21_77_1","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate\u2010to\u2010severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48\u2010week, randomised, double\u2010blind, placebo\u2010controlled, multicentre phase 3 trials","volume":"403","author":"Kimball AB","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"e_1_2_21_78_1","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jaad.2025.11.031","article-title":"Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2\u2009years of treatment in patients with moderate to severe hidradenitis suppurativa: pooled results from two phase 3 randomized, controlled trials and their open\u2010label extension","volume":"94","author":"Sayed CJ","year":"2026","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"e_1_2_21_79_1","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1007\/s13555-025-01465-4","article-title":"Bimekizumab impact on patient\u2010reported outcomes in patients with moderate to severe hidradenitis suppurativa: pooled 48\u2010week results from BE HEARD I&II","volume":"15","author":"Shi VY","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"e_1_2_21_80_1","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s40122-025-00779-7","article-title":"Bimekizumab pain outcomes in patients with hidradenitis suppurativa: pooled 48\u2010week results from BE HEARD I&II phase 3 randomized clinical trials","volume":"14","author":"Ingram JR","year":"2025","journal-title":"Pain Ther"},{"issue":"5","key":"e_1_2_21_81_1","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/jvc2.70083","article-title":"Sequencing of biologic therapy in hidradenitis suppurativa: a real\u2010world analysis of treatment in over 15,000 patients","volume":"4","author":"Pham J","year":"2025","journal-title":"JEADV Clin Pract"},{"issue":"7","key":"e_1_2_21_82_1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.5152\/tjg.2020.19295","article-title":"Risk of hepatitis B reactivation during anti\u2010TNF therapy;evaluation of patients with past hepatitis B infection","volume":"31","author":"Sayar S","year":"2020","journal-title":"Turk J Gastroenterol"},{"issue":"6","key":"e_1_2_21_83_1","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jaad.2024.09.027","article-title":"Biologics in hidradenitis suppurativa: progress and new directions","volume":"91","author":"Charrow A","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"e_1_2_21_84_1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1159\/000542217","article-title":"Biologics use for psoriasis during pregnancy and its related adverse outcomes in pregnant women and newborns: findings from WHO pharmacovigilance study","volume":"186","author":"Jeong YD","year":"2025","journal-title":"Int Arch Allergy Immunol"},{"key":"e_1_2_21_85_1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/CCID.S449367","article-title":"Secukinumab in hidradenitis suppurativa patients who failed adalimumab: a 52\u2010week real\u2010life study","volume":"17","author":"Martora F","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"e_1_2_21_86_1","doi-asserted-by":"crossref","DOI":"10.25251\/g776yf41","article-title":"Bimekizumab efficacy and safety through 3\u2009years in patients with hidradenitis suppurativa: results from the phase 3 BE HEARD I&II trials and their open\u2010label extension BE HEARD EXT","volume":"10","author":"Ingram JR","year":"2026","journal-title":"J of Skin"},{"issue":"6","key":"e_1_2_21_87_1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1177\/12034754251341846","article-title":"Therapeutic drug monitoring in hidradenitis suppurativa patients with suboptimal treatment response to adalimumab","volume":"29","author":"Stirton H","year":"2025","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"e_1_2_21_88_1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/12034754241308248","article-title":"Dose escalation of adalimumab in patients with hidradenitis suppurativa: a retrospective case series","volume":"29","author":"Caudrelier N","year":"2025","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"e_1_2_21_89_1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ijd.70025","article-title":"Secukinumab in the treatment of moderate\u2010to\u2010severe hidradenitis suppurativa: pooled pharmacokinetics and safety results from the SUNSHINE and SUNRISE phase 3 studies","volume":"65","author":"Alavi A","year":"2026","journal-title":"Int J Dermatol"},{"key":"e_1_2_21_90_1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jaad.2024.11.071","article-title":"North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations","volume":"92","author":"Alhusayen R","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"e_1_2_21_91_1","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/bjd\/ljae238","article-title":"Unravelling the complex pathogenesis of hidradenitis suppurativa","volume":"192","author":"Frew JW","year":"2025","journal-title":"Br J Dermatol"},{"issue":"1","key":"e_1_2_21_92_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat R","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"e_1_2_21_93_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/bjd\/ljad345","article-title":"Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape","volume":"190","author":"Krueger JG","year":"2024","journal-title":"Br J Dermatol"},{"issue":"4","key":"e_1_2_21_94_1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jaad.2023.11.048","article-title":"Tape strips detect molecular alterations and cutaneous biomarkers in skin of patients with hidradenitis suppurativa","volume":"90","author":"Navrazhina K","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"e_1_2_21_95_1","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jaci.2023.05.012","article-title":"Single\u2010cell transcriptomics suggest distinct upstream drivers of IL\u201017A\/F in hidradenitis versus psoriasis","volume":"152","author":"Kim J","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"e_1_2_21_96_1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL\u201017 receptor family","volume":"9","author":"Gaffen SL","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"e_1_2_21_97_1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/bjd\/ljad224","article-title":"Has the time come to assess small\u2010molecule\/biologic drug combinations for the management of moderate\u2010to\u2010severe hidradenitis suppurativa?","volume":"189","author":"Maronese CA","year":"2023","journal-title":"Br J Dermatol"},{"issue":"3","key":"e_1_2_21_98_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2023.07.345","article-title":"Secukinumab and concomitant antibiotic use in patients with moderate\u2010to\u2010severe hidradenitis suppurativa: week 16 efficacy and safety results from the phase 3 SUNSHINE and SUNRISE trials","volume":"89","author":"Kokolakis G","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"e_1_2_21_99_1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","article-title":"Comorbidity screening in hidradenitis suppurativa: evidence\u2010based recommendations from the US and Canadian hidradenitis suppurativa foundations","volume":"86","author":"Garg A","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"e_1_2_21_100_1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/bjd\/ljac107","article-title":"Adipokines as an important link between hidradenitis suppurativa and obesity: a narrative review","volume":"188","author":"Krajewski PK","year":"2023","journal-title":"Br J Dermatol"},{"issue":"8","key":"e_1_2_21_101_1","doi-asserted-by":"crossref","first-page":"e662","DOI":"10.1111\/jdv.20392","article-title":"Impact of semaglutide use in obese and diabetic patients with hidradenitis suppurativa","volume":"39","author":"Posada Posada MI","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"e_1_2_21_102_1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/bjd.17093","article-title":"Hormonal, stem cell and notch signalling as possible mechanisms of disease in hidradenitis suppurativa: a systems\u2010level transcriptomic analysis","volume":"180","author":"Gauntner TD","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"e_1_2_21_103_1","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/bjd.20520","article-title":"Novel evidence of androgen receptor immunoreactivity in skin tunnels of hidradenitis suppurativa: assessment of sex and individual variability","volume":"185","author":"Yu W","year":"2021","journal-title":"Br J Dermatol"},{"issue":"5","key":"e_1_2_21_104_1","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/jdv.14894","article-title":"Insulin resistance in hidradenitis suppurativa: a case\u2010control study","volume":"32","author":"Vilanova I","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"e_1_2_21_105_1","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.jaad.2025.12.092","article-title":"Glucagon\u2010like peptide\u20101 receptor agonists may decrease biologic initiation in hidradenitis suppurativa: a TriNetX retrospective analysis","volume":"94","author":"Kasheri E","year":"2026","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"e_1_2_21_106_1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/12034754251347592","article-title":"The use of hormonal therapies in patients with hidradenitis suppurativa: a systematic review","volume":"30","author":"Perlmutter JW","year":"2026","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"e_1_2_21_107_1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/1744666X.2023.2298356","article-title":"Biologics for hidradenitis suppurativa: evolution of the treatment paradigm","volume":"20","author":"Maronese CA","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"e_1_2_21_108_1","first-page":"885","article-title":"Guidelines how to integrate surgery and targeted therapy with biologics for the treatment of hidradenitis suppurativa: Delphi consensus statements from an Italian expert panel","volume":"240","author":"Offidani A","year":"2024","journal-title":"Dermatology"},{"issue":"4","key":"e_1_2_21_109_1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jaad.2023.04.034","article-title":"Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: a randomized controlled trial in a real\u2010world setting","volume":"89","author":"Aarts P","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"e_1_2_21_110_1","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamasurg.2020.2611","article-title":"Multidisciplinary update on genital hidradenitis suppurativa: a review","volume":"155","author":"Hamad J","year":"2020","journal-title":"JAMA Surg"},{"key":"e_1_2_21_111_1","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/6637006","article-title":"Combined biologic and surgical interventions for hidradenitis suppurativa: a systematic review","volume":"2024","author":"Issa CJ","year":"2024","journal-title":"Dermatol Ther"},{"issue":"8","key":"e_1_2_21_112_1","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/jdv.20550","article-title":"Hidradenitis suppurativa with and without draining tunnels: a real\u2010world study characterizing differences in treatment and disease burden","volume":"39","author":"Ingram JR","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"e_1_2_21_113_1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/jdv.18632","article-title":"Development and validation of IHS4\u201055, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa","volume":"37","author":"Tzellos T","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"e_1_2_21_114_1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bjd.18692","article-title":"The hidradenitis suppurativa quality of life (HiSQOL) score: development and validation of a measure for clinical trials","volume":"183","author":"Kirby JS","year":"2020","journal-title":"Br J Dermatol"},{"key":"e_1_2_21_115_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/bjd\/ljaf067","article-title":"Psychometric validation and interpretation thresholds of the hidradenitis suppurativa quality of life (HiSQOL\u00a9) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa","volume":"193","author":"Kirby JS","year":"2025","journal-title":"Br J Dermatol"},{"issue":"1","key":"e_1_2_21_116_1","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1111\/jdv.20794","article-title":"The WHO\u20105 well\u2010being measure as an assessment tool in eczema, hidradenitis suppurativa and psoriasis","volume":"40","author":"Pender E","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_21_117_1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/bjd\/ljag041","article-title":"Treat\u2010to\u2010target: optimizing outcomes for hidradenitis suppurativa","volume":"194","author":"Ingram JR","year":"2026","journal-title":"Br J Dermatol"},{"key":"e_1_2_21_118_1","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s13555-025-01457-4","article-title":"Management of Hidradenitis Suppurativa in special populations: a narrative review","volume":"15","author":"Mallela T","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"e_1_2_21_119_1","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/pde.70022","article-title":"Prevalence, age of onset, age at diagnosis, and family history of hidradenitis suppurativa in pediatric populations: a systematic review and meta\u2010analysis","volume":"42","author":"Xiong G","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"e_1_2_21_120_1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/pde.15404","article-title":"Efficacy of medical treatments for pediatric hidradenitis suppurativa: a systematic review","volume":"40","author":"Masson R","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"e_1_2_21_121_1","unstructured":"Novartis.Novartis Cosentyx receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa.2026. Available from:https:\/\/www.novartis.com\/us\u2010en\/news\/media\u2010releases\/novartis\u2010cosentyx\u2010receives\u2010fda\u2010approval\u2010pediatric\u2010patients\u2010aged\u201012\u2010moderate\u2010severe\u2010hidradenitis\u2010suppurativa."},{"key":"e_1_2_21_122_1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-025-00935-x","article-title":"A guide to the Management of Hidradenitis Suppurativa in pregnancy and lactation","volume":"26","author":"Ghanshani R","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"e_1_2_21_123_1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.36849\/JDD.6818","article-title":"Women of childbearing age with hidradenitis suppurativa frequently prescribed medications with pregnancy risk","volume":"22","author":"Rivin GM","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_21_124_1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1186\/s12879-014-0617-x","article-title":"Tuberculosis care for pregnant women: a systematic review","volume":"14","author":"Nguyen HT","year":"2014","journal-title":"BMC Infect Dis"},{"key":"e_1_2_21_125_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/phar.70010","article-title":"A review of antibiotic safety in pregnancy\u20102025 update","volume":"45","author":"Nguyen J","year":"2025","journal-title":"Pharmacotherapy"},{"key":"e_1_2_21_126_1","doi-asserted-by":"crossref","DOI":"10.1177\/2040622319851640","article-title":"TNF\u2010\u03b1 inhibitors in the treatment of hidradenitis suppurativa","volume":"10","author":"Savage KT","year":"2019","journal-title":"Ther Adv Chronic Dis"},{"key":"e_1_2_21_127_1","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/ijd.17672","article-title":"Hidradenitis suppurativa treatment during pregnancy and lactation: navigating challenges","volume":"64","author":"\u00d6zbek L","year":"2025","journal-title":"Int J Dermatol"},{"key":"e_1_2_21_128_1","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/ecco-jcc\/jjac093","article-title":"Timing of live attenuated vaccination in infants exposed to infliximab or adalimumab in utero: a prospective cohort study in 107 children","volume":"16","author":"Liu Z","year":"2022","journal-title":"J Crohns Colitis"},{"key":"e_1_2_21_129_1","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1111\/ijd.15286","article-title":"Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy","volume":"60","author":"Wohlmuth\u2010Wieser I","year":"2021","journal-title":"Int J Dermatol"},{"key":"e_1_2_21_130_1","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3899\/jrheum.130977","article-title":"Hidradenitis suppurativa associated with spondyloarthritis\u2010\u2010results from a multicenter national prospective study","volume":"41","author":"Richette P","year":"2014","journal-title":"J Rheumatol"},{"key":"e_1_2_21_131_1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1177\/12034754251320638","article-title":"Inflammatory bowel disease following IL\u201017 inhibitor exposure for psoriatic disease and hidradenitis suppurativa: a systematic review","volume":"29","author":"Dienes S","year":"2025","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"e_1_2_21_132_1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40257-024-00880-1","article-title":"Hidradenitis suppurativa: new targets and emerging treatments","volume":"25","author":"Gao JL","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"e_1_2_21_133_1","doi-asserted-by":"crossref","DOI":"10.2147\/CCID.S591676","article-title":"Effectiveness and safety of antidiabetic medications in hidradenitis suppurativa: a systematic review","volume":"19","author":"Almukhadeb E","year":"2026","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10","key":"e_1_2_21_134_1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive platform trials: definition, design, conduct and reporting considerations","volume":"18","author":"Adaptive Platform Trials Coalition","year":"2019","journal-title":"Nat Rev Drug Discov"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70787","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70787","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:55:23Z","timestamp":1791874523000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":133,"alternative-id":["10.1111\/jdv.70787"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70787","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"2026-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jdv.70787"}}